AviadoBio
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
86 Hatton Gdn Fl 5, London, Greater Lond...Website
www.aviadobio.comRevenue
$10.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About AviadoBio
Founded in 2019, and based in London, UK, is a gene therapy company with a focus in neurological diseases.Explore more
AviadoBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AviadoBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on AviadoBio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at AviadoBio
Product Launch: Get notified when AviadoBio launches new products
Check out if AviadoBio is spiking on competitors!
Click to see if AviadoBio had a recent Job posting/layoffs
Check if AviadoBio has recently received funding, and reach out quickly before it becomes old news!
AviadoBio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once AviadoBio has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to AviadoBio
Compare insights from companies similar to AviadoBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AviadoBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AviadoBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AviadoBio.
AviadoBio financials insights
Gather financial insights about AviadoBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$80M
AviadoBio Tech Stack
A closer look at the technologies used by AviadoBio
See more technologies
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Person-Based
Person-Based
AviadoBio News & Media
AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced the completion of the second dose cohort in its Phase 1/2 ASPIRE-FTD clinical trial. ASPIRE-FTD is evaluating multiple doses of AviadoBio’s investigational gene therapy, AVB-101, in people living with frontotemporal dementia (FTD) with GRN gene mutations (FTD-GRN). The company intends to initiate dosingAstellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development AviadoBio receives $20 million equity investment, up to $30 million in upfront payments and is eligible to receive up to $2.18 billion in license fees and...ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University. ASPIRE-FTD is evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). ThAviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the first patient has been treated in the Phase 1/2 ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). Clinical trial sites are currently open in Poland, Spain, and the Netherla
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AviadoBio
Sign Up For FreeTo access detailed company insights
Founded in 2019, and based in London, UK, is a gene therapy company with a focus in neurological diseases.... Read More
